MARKET

CLVLY

CLVLY

Clinuvl Phrmaceu
OTCPK
6.30
-0.65
-9.35%
Closed 15:39 04/10 EDT
OPEN
6.30
PREV CLOSE
6.95
HIGH
6.30
LOW
6.30
VOLUME
300
TURNOVER
1.89K
52 WEEK HIGH
8.92
52 WEEK LOW
6.07
MARKET CAP
316.26M
P/E (TTM)
14.66
1D
5D
1M
3M
1Y
5Y
1D
Clinuvel Pharmaceuticals reports 2H results
Seeking Alpha · 02/26 17:08
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
Barchart · 12/07/2025 20:37
These Healthcare Stocks Just Exploded In Momentum — Investors Are Taking Notice
Benzinga · 12/03/2025 20:57
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
Barchart · 09/28/2025 21:56
Weekly Report: what happened at CLVLY last week (0908-0912)?
Weekly Report · 09/15/2025 11:36
Weekly Report: what happened at CLVLY last week (0901-0905)?
Weekly Report · 09/08/2025 11:38
Weekly Report: what happened at CLVLY last week (0825-0829)?
Weekly Report · 09/01/2025 11:32
Clinuvel Pharmaceuticals reports FY results
Seeking Alpha · 08/28/2025 13:07
More
About CLVLY
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.

Webull offers Clinuvel Pharmaceuticals Ltd (ADR) stock information, including OTCPK: CLVLY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVLY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLVLY stock methods without spending real money on the virtual paper trading platform.